National Hansen's Disease Programs
1770 Physicians Park Drive
Baton Rouge, Louisiana
This online course presented by the National Hansen’s Disease Programs is designed to increase health care providers’ awareness of this unique and misunderstood disease.
Although Hansen's disease (HD), more commonly known as leprosy, is not a common infectious disease, it has not been eradicated from the U.S. population. HD is endemic in the U.S., particularly in the Gulf Coast region, with 100 to 150 new cases diagnosed each year.
Fifty years ago, cases were detected in the port cities and the Gulf Coast region. These patients with the disease were institutionalized to the Gillis W. Long Hansen’s Disease Center, located in Carville, Louisiana. This is no longer the case and patients are no longer institutionalized. HD is primarily treated on an outpatient basis and more cases are being detected in the heartland of the country. This fact increases the likelihood that those in the general medical community may encounter one or more cases of HD and find this information useful in the detection and management of the disease.
This online course is intended to:
Upon completion, the participant should:
Credit: 1 Contact Hour
C.M.E. Applied For:
(CME Credit is only available to physicians at this time)
This online course has been approved for 1.5 C.M.E. Credits by the American Academy of Family Physicians
(AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit toward the AMA Physicians’ Recognition Award.)
Interactive Online course Application Form (PDF - 222 KB).
Participants will be provided an online username and password and have 24 hour a day access to the course materials. The site contains PowerPoint Presentations, notes, a discussion area and post-tests. Once enrolled, all modules and post-tests must be completed within 2 weeks. Upon satisfactory completion of the course, participants will be mailed a CME certificate of completion.
James Krahenbuhl, PhD – Former Director, National Hansen's Disease Programs
Dr. Krahenbuhl has 35 years experience in leprosy research and general leprosy expertise. He has authored 120 peer-reviewed publications and 180 peer-reviewed scientific presentations.
He has lectured numerous times on this subject and has organized comprehensive seminars on the need for leprosy awareness in Springdale, Arkansas; the Lahey Clinic in Boston, Emory University in Atlanta and the NIH Clinical Center in Bethesda, Maryland.
As Director of the NHDP, a top training priority has been to increase the awareness that leprosy (Hansen’s Disease) does still exist in the U.S. and that the NHDP provides diagnostic, treatment, management and consultative services that assist private sector health care givers to manage cases of leprosy.
David Scollard, M.D., PhD – Director, National Hansen's Disease Programs
After receiving M.D. and Ph.D. (Pathology / Immunology) degrees from the Pritzker School of Medicine at the University of Chicago, Dr. Scollard, completed a one year of residency in Internal Medicine. He has taught pathology at the University of Hong Kong, the University of Hawaii, and currently at Louisiana State University in New Orleans.
Starting with a leprosy research interest at the University of Hong Kong in the late 1970s, he participated as Field Director for the combined Chiang Mai Uni. versity / University of Illinois Leprosy research project in Thailand.
Dr. Scollard has more than 30 years’ experience in leprosy work in the field, clinic, and laboratory venues. He has over 60 peer-reviewed publications and has authored several book chapters on leprosy and was the Editor of the International Journal of Leprosy from 2003-2005.
He was the Chief of Pathology for the NHDP Laboratory Research Branch from 1993-2008.
Barbara Stryjewska, M.D. – Chief, Clinical Branch, NHDP
Dr. Stryjewska obtained her medical doctorate in 1977 from the Jagiellonian University School of Medicine in Krakow, Poland. After completing her residency in Radiation Oncology, she served as an attending on the Oncology Service at the Centre of Oncology at the Curie Memorial Institute in Krakow until her immigration to the United States in 1988.
After immigrating to the U.S., she retrained in Family Medicine at St. Joseph's Medical Center in Yonkers, New York. She served as a Primary Care Provider in Baton Rouge, Louisiana until 2002, when she assumed the position of Director of Medical Services for the National Hansen’s Disease Program Clinical Branch, the only facility in the United States solely devoted to the treatment of leprosy.
In addition to her duties coordinating the overall care of Hansen’s disease patients who are seen at NHDP, Dr. Stryjewska also provides consulting support to physicians and health departments around the country and she regularly leads educational seminars on the medical, surgical and therapeutic management of leprosy.
John F. Prestigiacomo, MD, MBA – NHDP Blackboard Instructor
"Awareness of Hansen's Disease in U.S." Course Developer
After receiving an undergraduate B.A. Degree in Chemistry, Dr. Prestigiacomo attended Louisiana State University (LSU) Medical School in New Orleans, Louisiana receiving his MD degree in 1983. He then completed three years of postgraduate residency training in Family Medicine at both Charity Hospital and Hotel Dieu Hospital (now called University Hospital) in New Orleans as part of the LSU Medical Center Family Medicine Residency Program. In January 2000, Dr. Prestigiacomo began participating in a joint pilot MBA educational program initiated by the LSU E.J. Ourso College of Business and Our Lady of the Lake Regional Medical Center. In December 2002, Dr. Prestigiacomo was awarded his Masters of Business Administration degree.
Since graduating from the LSU Family Medicine Residency Program, Dr. Prestigiacomo has served as a Primary Care Provider in the Greater Baton Rouge, Louisiana area.
In October 2006, Dr. Prestigiacomo assumed a part-time staff position with the National Hansen’s Disease Program. He serves as a Medical Officer involved in the diagnosis and treatment of new and ongoing cases of Hansen’s Disease.